Navigation Links
Timothy I. Still Appointed CEO at Accumetrics
Date:10/30/2008

SAN DIEGO, Oct. 30 /PRNewswire/ -- Accumetrics, Inc. has appointed Timothy I. Still to the additional position of Chief Executive Officer. Mr. Still has been serving in the capacity of President and Chief Operating Officer for the company since earlier this year.

"Tim has the right combination of industry, management, and startup experience for our Board," says Tony Arnerich, General Partner of Arnerich & Massena and Executive Chairman of the Board at Accumetrics. "His commercialization expertise and diagnostic market experience will be invaluable as we build key partnerships and move forward with the commercialization of our technology."

Mr. Still's background includes over 18 years of sales, marketing and business development experience in healthcare and medical diagnostics. He has extensive experience in designing and implementing highly focused sales and marketing strategies within both large and small companies.

Prior to Accumetrics, Mr. Still was Executive Vice President and Chief Commercial Officer for HemoSense, a medical diagnostic company located in San Jose, California. He was instrumental in building HemoSense into a rapidly growing, publicly traded company which was acquired by Inverness Medical in November 2007.

Before joining HemoSense, Mr. Still served as Vice President of Sales and Marketing for Cholestech Corporation, and served in a variety of sales, marketing and business development roles for Boehringer Mannheim Corporation (now Roche Diagnostics).

Mr. Still received a B.S. degree (with Honors) in Biological Sciences from the University of California at Davis, and an MBA (Deans Scholar) in Marketing and Entrepreneurship from the University of Southern California.

About Accumetrics (http://www.accumetrics.com):

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients rece
'/>"/>

SOURCE Accumetrics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. HeartWare Appoints Timothy J. Barberich to Board of Directors
2. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
3. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
4. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
5. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
6. Excalibur - Transforming Biotech Deals can Still be Achieved
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. Still River Systems Announces Operation of the Worlds Highest Magnetic Field Cyclotron
9. Federal nanotech risk research plan still comes up short
10. Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated
11. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...ewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, IN...an update on its European commercial launch of MuG... a debilitating side effect of radiation treatment... by Access, partner, SpePharm, in six European cou...Greece and Sweden. Access is conducting pre-market...
(Date:12/3/2009)...3 Peregrine Pharmaceutic... will release its financial results for the second...at 7:00 a.m. EST and will host a conference call a...T on the same day. ,, Peregrine,s senior manage... quarter ended October 31, 2009 and will review re...
(Date:12/3/2009)...dia, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, ...ke Biotechnology Co. Ltd.,( http://www.beikebiotec...tic,Foot Care in New Delhi, India, November 22, 20...d regenerative medicine company. , The co...tion (IPA), aimed,to help podiatrists and research...
(Date:12/2/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, Neurostimulation - A Global Market Pe...4232/Neurostimulation---A-Global-Market-Perspectiv...tands enthused by the growing base of aging popula...es such as, Parkinson,s, and Alzheimer,s disease. ...
Breaking Biology Technology:Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6
...Probe,s Commercial Expansion in, Fast-Growing Euro...ies and Markers -, ...t Standalone Molecular, Diagnostics Company, Provi... Diverse Customer Needs Around the Worl...asdaq: GPRO ), a pioneer and leader in nucleic ac...
...fted to maneuver separately without any obvious gu...ctures after years of continuing research led by a...elous to be able to do assembly and control at thi...gs," said Bruce Donald, a Duke professor of comput... shaped something like a spatula but with dimensio...
..., June 3, 2008, TIME: 9:30 a.m. Eastern Tim...EO Kendle (Nasdaq: KNDL ) will conduct a telepho...sday, June 3 at 9:30 a.m. Eastern Time to,discuss ...Corporation that,was announced on May 30 and to pr...tion and answer session will follow., (Logo: htt...
Other Biology Technology:Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics 2Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics 3Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics 4Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics 5Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics 6Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics 7Microrobots dance on something smaller than a pin's head 2Microrobots dance on something smaller than a pin's head 3Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress 2
(Date:12/2/2009)... identification of substances involved in the Jeky...arine bacteria into killers that cause "coral blea... Science & Technology , a semi-monthly journal. ,...lready has destroyed up to 30 percent of the world...ays to slow or stop the damage. One known culprit ...
(Date:12/2/2009)...alif. and PALM HARBOR, Fla., Dec. 2 /PRNewswire-Fi... ("CIC") (OTC Bulletin Board: CICI), a leading sup...ss process automation in the financial industry* a...verification and Docubase Systems Inc. ("Docubase"...agement (EDM) software provider announced today th...
(Date:12/2/2009)...f carbon about a nanometer in diameterhave been hi...rastrong fibers, electrical wires in molecular dev...s. Thanks to a new development by researchers at t...(NIST) and five partners, you can add one more app... an aggressive form of breast cancer. , HER2 is ...
Breaking Biology News(10 mins):CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4Combining nanotubes and antibodies for breast cancer 'search and destroy' missions 2Red Cross Leader Describes First Year Triumphs Challenges 52332 1Red Cross Leader Describes First Year Triumphs Challenges 52332 2Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 1Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 2Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 3Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 4Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 5Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 6Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 7Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 8Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 9Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 10Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 11Amylin Pharmaceuticals Reports Second Quarter Financial Results 52326 12University HealthSystem Consortium Recognized as a Company That Cares for Sixth Year in a Row 52321 1University HealthSystem Consortium Recognized as a Company That Cares for Sixth Year in a Row 52321 2
...dy, led by Grace Gill, PhD, Tufts University Schoo...n called SUMO (Small Ubiquitin-related Modifier) g...of chromatin to regulate expression of genes. Chro...make up chromosomes. The interaction between SUMO ... of cancer and neurodegenerative diseases such as ...
...something of an enigma that our brain can achieve ...ch lies at the interface between vision and langua...ought to have been invented only around four to fi...has elapsed to allow the evolution of specialized ... techniques have made some progress in understandi...
...ral Physiology features an article and accompanyi...vances previous conclusions about the essential fe...otassium (Kv) channel. , As Richard Horn (Departm...ute of Hyperexcitability, Jefferson Medical Colleg...he essential features of the voltage-sensing mecha...
Other Biology News:SUMO protein guides chromatin remodeler to suppress genes 2Early brain activity sheds new light on the neural basis of reading 2Early brain activity sheds new light on the neural basis of reading 3
Scaffold Software from Proteome Software Inc.
Normal Goat Serum from Calbiochem
TRIzol LS Reagent from Invitrogen
UltraPure DNase/RNase-Free Distilled Water from Invitrogen
Biology Products: